Anika Therapeutics completed the acquisition of Parcus Medical and Arthrosurface for $170m.

Anika Therapeutics, a global, integrated joint preservation and regenerative therapies company, completed the acquisition of Parcus Medical and Arthrosurface, two medicine companies, for $170m, including $75m in contingent considerations. “This acquisition immediately adds a diverse base of high-growth revenue and will help us achieve the objectives we set forth in our five-year strategic plan. We can now turn our attention to executing our integration plan and continuing to transform Anika into a leading global sports and regenerative medicine company,” Joseph Darling, Anika Therapeutics President and Chief Executive Officer.